ERBB2 and cancer: Since EGF can bind to receptors other than EGFR, such as ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4) across most cancer contexts, and is a key player in cancer metastasis [148], it is likely that the EGF-associated mechanisms driving EMT are distinct from those regulating MHC I expression.